

| | | |
|------------|---|--|
| STN | Molekulárno-diagnostické vyšetrenia in vitro Špecifikácie postupov pred vyšetrením formalínom fixovaného a parafrínom zaliateho (FFPE) tkaniva Časť 4: Techniky detekcie in situ (ISO 20166-4: 2021) | STN EN ISO 20166-4 85 6574 |
|------------|---|--|

Molecular in vitro diagnostic examinations - Specifications for preexamination processes for formalin-fixed and paraffin-embedded (FFPE) tissue - Part 4: In situ detection techniques (ISO 20166-4:2021)

Táto norma obsahuje anglickú verziu európskej normy.
This standard includes the English version of the European Standard.

Táto norma bola oznámená vo Vestníku ÚNMS SR č. 09/21

Obsahuje: EN ISO 20166-4:2021, ISO 20166-4:2021

133686

EUROPEAN STANDARD

EN ISO 20166-4

NORME EUROPÉENNE

EUROPÄISCHE NORM

July 2021

ICS 11.100.10

English Version

**Molecular in vitro diagnostic examinations - Specifications
for preexamination processes for formalin-fixed and
paraffin-embedded (FFPE) tissue - Part 4: In situ detection
techniques (ISO 20166-4:2021)**

Analyses de diagnostic moléculaire in vitro -
Spécifications relatives aux processus préanalytiques
pour les tissus fixés au formol et inclus en paraffine
(FFPE) - Partie 4: Techniques de détection in situ (ISO
20166-4:2021)

Molekularanalytische in-vitro-diagnostische Verfahren
- Spezifikationen für präanalytische Prozesse für
formalinfixierte und paraffineingebettete (FFPE-)
Gewebeproben - Teil 4: In-situ-Detektionstechniken
(ISO 20166-4:2021)

This European Standard was approved by CEN on 20 May 2021.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

Contents

Page

European foreword..... 3

European foreword

This document (EN ISO 20166-4:2021) has been prepared by Technical Committee ISO/TC 212 "Clinical laboratory testing and in vitro diagnostic test systems" in collaboration with Technical Committee CEN/TC 140 "In vitro diagnostic medical devices" the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by January 2022, and conflicting national standards shall be withdrawn at the latest by July 2024.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

Any feedback and questions on this document should be directed to the users' national standards body/national committee. A complete listing of these bodies can be found on the CEN websites.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of ISO 20166-4:2021 has been approved by CEN as EN ISO 20166-4:2021 without any modification.

**INTERNATIONAL
STANDARD**

**ISO
20166-4**

First edition
2021-07

**Molecular in vitro diagnostic
examinations — Specifications
for preexamination processes for
formalin-fixed and paraffin-embedded
(FFPE) tissue —**

**Part 4:
In situ detection techniques**

*Analyses de diagnostic moléculaire in vitro — Spécifications relatives
aux processus préanalytiques pour les tissus fixés au formol et inclus
en paraffine (FFPE) —*

Partie 4: Techniques de détection in situ



Reference number
ISO 20166-4:2021(E)

© ISO 2021

ISO 20166-4:2021(E)**COPYRIGHT PROTECTED DOCUMENT**

© ISO 2021

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

Page

| | |
|--|-----------|
| Foreword | iv |
| Introduction | v |
| 1 Scope | 1 |
| 2 Normative references | 1 |
| 3 Terms and definitions | 1 |
| 4 General considerations | 8 |
| 5 Activities outside the laboratory | 10 |
| 5.1 Specimen collection..... | 10 |
| 5.1.1 General..... | 10 |
| 5.1.2 Information about the patient/specimen donor..... | 10 |
| 5.1.3 Information about the specimen..... | 10 |
| 5.1.4 Specimen processing, intermediate storage and preparation for transport..... | 11 |
| 5.2 Transport..... | 12 |
| 6 Activities inside the laboratory | 12 |
| 6.1 Specimen reception..... | 12 |
| 6.2 Formalin fixation of the specimen or sample(s)..... | 12 |
| 6.3 Evaluation of the pathology of the specimen and selection of the sample(s)..... | 13 |
| 6.3.1 General..... | 13 |
| 6.3.2 Macroscopic evaluation..... | 14 |
| 6.3.3 Selection of the sample(s)..... | 14 |
| 6.4 Post-fixation of frozen samples from intraoperative consultation..... | 15 |
| 6.5 Sample decalcification/softening..... | 15 |
| 6.6 Tissue processing and paraffin embedding..... | 16 |
| 6.6.1 General..... | 16 |
| 6.6.2 Dehydration and clearing..... | 16 |
| 6.6.3 Impregnation with paraffin and paraffin embedding..... | 17 |
| 6.7 Storage of FFPE tissue blocks..... | 17 |
| 6.8 Sectioning of FFPE tissue blocks and storage of slide-mounted sections..... | 18 |
| 6.9 Deparaffinization and rehydration of slide-mounted sections..... | 19 |
| 6.10 Pretreatment of slide-mounted sections for in situ detection techniques..... | 19 |
| 6.10.1 General..... | 19 |
| 6.10.2 Pretreatment for antibody- or other affinity binder-based in situ detection techniques..... | 19 |
| 6.10.3 Pretreatment for hybridization-based in situ detection techniques..... | 20 |
| 6.10.4 Pretreatment for other in situ detection techniques..... | 20 |
| 6.11 Quality assessment of the pre-analytical part of in situ detection..... | 20 |
| Annex A (informative) Recommendations relating to verification and validation of laboratory developed in situ detection tests | 21 |
| Annex B (informative) Example protocol for tissue processing | 22 |
| Bibliography | 23 |

ISO 20166-4:2021(E)

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 212, *Clinical laboratory testing and in vitro diagnostic test systems*.

A list of all parts in the ISO 20166 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

Molecular in vitro diagnostics, including molecular pathology, has enabled significant progress in medicine. Further progress is expected by new technologies analyzing tissue morphology and biomolecules, such as (e.g. proteins, DNA, RNA and/or metabolites (e.g. glucose) in human tissues and body fluids.

In pathology, the majority of diagnoses are based on in situ staining of formalin-fixed and paraffin-embedded (FFPE) tissue sections. In the context of personalized medicine, classical histological staining (e.g. hematoxylin and eosin) for morphological evaluation is increasingly complemented by additional in situ detection techniques, such as immunohistochemistry or in situ hybridization, as well as molecular analysis of isolated biomolecules. For example, many regulatory bodies approved companion diagnostics in oncology are based on in situ detection techniques applied on FFPE tissue sections. Developments in personalized medicine and new technologies, such as multi-label immunostaining and computer-based analysis of digital images (e.g. generated by using a slide scanner) pose new requirements on standardization of pre-analytical procedures to obtain reproducible qualitative and quantitative results.

Profiles and/or integrity of biomolecules and their in situ localization, amount and accessibility for in situ detection in tissues can change drastically during the pre-examination process comprising specimen collection, tissue processing, embedding, transport, storage, sectioning and pretreatment for in situ detection. This makes the outcome from in situ detection in diagnostics or research unreliable or even impossible because the subsequent examination will not represent the in vivo state of molecules, but instead, an artificial profile or morphology generated during the pre-examination process.

Therefore, a standardization of the entire pre-examination process of FFPE tissue specimens intended for in situ examinations of morphology and biomolecules on FFPE tissue sections by using different in situ detection techniques, is needed.

There is multiple scientific evidence that several factors of the pre-examination phase influence the outcome (e.g. quality or quantity in terms of specificity or sensitivity) of in situ detection and, thus, can have major impact on the diagnostic results.

This document draws upon such work to organize and standardize the steps for formalin-fixed and paraffin-embedded (FFPE) tissue with regard to various in situ detection techniques in what is referred to as the pre-examination phase. This document is for the pre-examination phase of in situ detection techniques and is applicable to the whole spectrum of in situ detection techniques.

These include but are not limited to:

- Classical histological staining, e.g. Hematoxylin & Eosin staining (H&E);
- Histochemical techniques, e.g. Lipid staining, Periodic Acid Schiff (PAS) reaction, Perls' Prussian Blue reaction, Feulgen's reaction, enzyme histochemistry;
- Immunohistochemical staining (IHC) or immunofluorescence staining using antibodies (polyclonal, monoclonal or recombinant antibodies) or other affinity binders;
- Hybridization-based techniques such as RNA or DNA in situ hybridization (ISH) techniques, e.g. fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH), or silver enhanced in situ hybridization (SISH);
- Molecular analysis of isolated biomolecules that can be mapped to a defined region of an FFPE section (by e.g. in situ sequencing, imaging mass spectrometry).

In this document, the following verbal forms are used:

- "shall" indicates a requirement;
- "should" indicates a recommendation;

ISO 20166-4:2021(E)

- "may" indicates a permission;
- "can" indicates a possibility or a capability.

Molecular in vitro diagnostic examinations — Specifications for preexamination processes for formalin- fixed and paraffin-embedded (FFPE) tissue —

Part 4: In situ detection techniques

1 Scope

This document specifies requirements and gives recommendations for the collection, handling, documentation, transport, storage and processing during the pre-examination phase of formalin-fixed and paraffin-embedded (FFPE) tissue specimens intended for qualitative and/or (semi-)quantitative in situ examination of the morphology and of biomolecules, such as metabolites, proteins, DNA and/or RNA, on FFPE tissue sections by using different in situ detection techniques.

This document is applicable to in vitro diagnostic examinations using in situ detection techniques. These include laboratory developed tests performed by pathology laboratories (histopathology laboratories) as well as by molecular pathology laboratories and other medical laboratories. It is also intended to be used by laboratory customers, in vitro diagnostics developers and manufacturers, biobanks, as well as institutions and commercial organizations performing biomedical research, and regulatory authorities.

This document is not applicable to the pre-examination phase of RNA, proteins and DNA isolated from FFPE tissue for examination. These are covered in ISO 20166-1, ISO 20166-2 and ISO 20166-3, Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for isolated RNA, proteins and DNA, respectively.

Different dedicated measures are taken for pre-examination processes for fine needle aspirates (FNAs). These are covered in CEN WI 00140128, CEN WI 00140126, and CEN WI 00140129, Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for Fine Needle Aspirates (FNAs) isolated cellular RNA, isolated proteins, and isolated genomic DNA, respectively.

NOTE International, national or regional regulations or requirements can also apply to specific topics covered in this document.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 15189, *Medical laboratories — Requirements for quality and competence*

ISO 15190, *Medical laboratories — Requirements for safety*

koniec náhľadu – text ďalej pokračuje v platenej verzii STN